JP3031692B2 - Novel peptide, method for producing it and use - Google Patents

Description

The present invention provides a novel peptide having the following structure, and relates to a peptide useful as an angiotensin converting enzyme inhibitor or the like.

Asp-Tyr-Gly-Leu-Tyr-Pro [Prior Art] Angiotensin converting enzyme is mainly present in lung, vascular endothelial cells, and renal proximal tubules, and angiotensin I (As
Acts on p-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) to release the dipeptide (His ⁹ -Leu ¹⁰ ) from the C-terminus of angiotensin I and has a strong pressor action It is an enzyme that produces angiotensin II. This enzyme also has the action of destroying and inactivating bradykinin, which is a hypotensive substance in the living body, and is strongly involved in the pressor system.

Hitherto, it has been considered that inhibiting the activity of an angiotensin converting enzyme acts on blood pressure lowering, and is clinically effective for preventing and treating hypertension.

Recently, since captopril, a proline derivative, has been synthesized and its antihypertensive activity has been confirmed, studies on the synthesis of various angiotensin converting enzyme inhibitors have been actively conducted, and attempts are being made to obtain them from natural products.

This is because a natural product-derived angiotensin converting enzyme inhibitor can be obtained from food or food raw material, and is therefore expected to be a low-toxin and highly safe antihypertensive agent.

[Problems to be Solved by the Invention] However, angiotensin converting enzyme inhibitors found in natural products are extremely rare, such as teprotide (nonapeptide, SQ20881) slightly obtained from Brazilian or Japanese snake venom, and Streptomyces. Only the metabolite IS83 of the genus Actinomycetes belonging to the genus (JP-A-58-177920) is known. Also, as angiotensin converting enzyme inhibitors obtained by enzymatic treatment of natural products, peptides and the like obtained by decomposing milk casein with trypsin are known (JP-A-58-109425, JP-A-58-109425). −44323,
No. 59-44324, No. 61-36226, No. 61-36227) The development of new inhibitors is being demanded.

[Means for Solving the Problems] The present inventors have intensively searched for an angiotensin converting enzyme inhibitor which is a natural substance and has few side effects in order to solve such problems, and as a result, hydrolyze proteins, particularly fish meat and cutlet bean, with specific enzymes. The presence of a substance having angiotensin converting enzyme inhibitory activity in the resulting composition,
The present inventors have found that the peptide has -Tyr-Gly-Leu-Tyr-Pro as a skeleton and completed the present invention.

The peptide of the present invention, Asp-Tyr-Gly-Leu-Tyr-Pro, is a novel peptide not described in the literature, and is produced by hydrolyzing proteins such as skipjack and the like with thermolysin. And may be used after purification if necessary. Furthermore, it can also be produced by synthesizing by applying conventional means of peptide synthesis.

Leu means leucine, Tyr means tyrosine, Pro means proline, Asp means aspartic acid, Gly means glycine, and these amino acids are all in L-form.

The peptide of the present invention can be obtained by hydrolyzing a protein with thermolysin or by a peptide synthesis method. To hydrolyze the protein with thermolysin, the formulation differs depending on the properties of the protein.If it is hardly soluble, mix the protein with hot water, homogenize with vigorous stirring, add a predetermined amount of thermolysin, and add a temperature of 10 to 85 ° C. Perform the reaction for about 0.1 to 48 hours.

As the protein, those derived from animals or microorganisms are arbitrarily used, and particularly useful ones are fish such as skipjack and sardines. In the hydrolyzate, in addition to the peptide of the present invention, other peptides are present.These peptides may be used as a mixture for various purposes, or only the peptide of the present invention may be isolated and used. No problem.

In the case of isolation, the hydrolyzed solution is filtered by a known operation such as centrifugation. After the application of extraction, concentration, drying, etc., with or without application, differences in adsorption affinity for various adsorbents, differences in solubility or solubility in various solvents, two immiscible liquid phases It is preferable to isolate the target compound by applying a means utilizing a difference in distribution between molecules, a difference in elution rate based on the size of a molecule, a property of precipitation from a solution or a difference in deposition rate. These methods may be used alone as needed or combined in any order and applied repeatedly.

The peptide of the present invention is a raw material having a reactive carboxyl group corresponding to one of two fragments bisected at an arbitrary position of a peptide bond by a method usually used for peptide synthesis, that is, a liquid phase method or a solid phase method, It is also produced by condensing a raw material having a reactive amino group corresponding to the other fragment using a carbodiimide method, an active ester method, or the like, and, if the condensate formed has a protective group, removing the protective group. obtain.

Functional groups that should not take part in the reaction in this reaction step are protected by protecting groups. Examples of the amino-protecting group include benzyloxycarbonyl, t-butyloxycarbonyl, p-biphenylisopropyloxycarbonyl, 9-fluorenylmethyloxycarbonyl and the like. Examples of the carboxyl group-protecting group include groups capable of forming an alkyl ester, a benzyl ester and the like. In the case of the solid phase method, the C-terminal carboxyl group is a chloromethyl resin, an oxymethyl resin, a p-alkoxybenzyl alcohol resin. And the like.

The condensation reaction is carried out in the presence of a condensing agent such as carbodiimide or using an N-protected amino acid active ester or peptide active ester.

After completion of the condensation reaction, the protecting group is removed, but in the case of the solid phase method, the bond between the C-terminal of the peptide and the resin is further cleaved.

Further, the peptide of the present invention is purified according to a usual method. For example, ion exchange chromatography, reverse phase liquid chromatography, affinity chromatography and the like can be mentioned.

The administration route of the peptide used in the present invention may be any of oral administration, parenteral administration and rectal administration, but oral administration is preferred. The dose of the peptide of the present invention varies depending on the type of the compound, the administration method, the symptoms and age of the patient, etc., but is usually 0.001 to 1000 mg, preferably 0.01 to 10 mg once a day, 1 to 3 times a day. The peptide of the present invention is generally
It is administered in the form of a preparation prepared by mixing with a preparation carrier.
As the pharmaceutical carrier, a substance which is commonly used in the pharmaceutical field and does not react with the peptide of the present invention is used. Specifically, for example, lactose, glucose, mannitol, dextrin, cyclodextrin, starch, sucrose, magnesium metasilicate aluminate, synthetic aluminum silicate,
Carboxymethylcellulose sodium, hydroxypropyl starch, carboxymethylcellulose calcium, ion exchange resin, methylcellulose, gelatin, gum arabic, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone,
Polyvinyl alcohol, light anhydrous silicic acid, magnesium stearate, talc, tragacanth, bentonite, veegum, titanium oxide, sorbitan fatty acid ester, sodium lauryl sulfate, glycerin, fatty acid glycerin ester, purified lanolin, glycerogelatin, polysorbate, macrogol, vegetable oil, Wax, liquid paraffin,
Examples include white petrolatum, fluorocarbon, nonionic surfactant, propylene glycol, water and the like. Dosage forms include tablets, capsules, granules, powders, syrups, suspensions, suppositories, ointments, creams, gels, patches, inhalants, injections, and the like. These preparations are prepared according to a conventional method. In the case of a liquid preparation, it may be in the form of being dissolved or suspended in water or another appropriate medium at the time of use. Tablets and granules may be coated by a known method. In the case of an injection, the peptide of the present invention is prepared by dissolving the peptide in water, but may be dissolved in a physiological saline solution or a glucose solution if necessary, or may be added with a buffer or a preservative. Good.

These preparations can contain the peptide of the present invention at a rate of 0.01% or more, preferably 0.5 to 70%. These formulations may also contain other therapeutically valuable components.

[Action] The peptide of the present invention is a novel peptide and has an excellent angiotensin converting enzyme inhibitory action, exhibits a blood pressure lowering action, a bradykinin inactivation inhibitory action, and has essential hypertension, renal hypertension, adrenal hypertension, etc. Prevention of hypertension,
It is useful as a therapeutic agent, a diagnostic agent for these diseases and an antihypertensive agent used in various disease states, an increase in the threshold of angina attack, a decrease in myocardial infarction, and an improvement agent for disease states in congestive heart failure.

[Examples] Next, the present invention will be described more specifically with reference to actual examples.

(Synthesis of peptide)

Commercially available Boc (butoxycarbonyl) -Pro-O-Resin
0.83 g was collected in a reaction vessel of a peptide synthesizer SAM2 manufactured by Biosearch and synthesized as follows.

After removing the Boc group by reaction in methylene chloride containing 45% trifluoroacetic acid and 2.5% anisole for 25 minutes, washing with methylene chloride, neutralization with methylene chloride containing 10% diisopropylethylamine, and washing with methylene chloride Was done.

This was mixed with 5 ml of a 0.4 M solution of 0.4 M Boc-Tyr (Cl ₂ -Bzl) (dichlorobenzyl group) in dimethylformamide and 5 ml of a 0.4 M solution of 0.4 M diisopropylcarbodiimide in methylene chloride, and then added to the reaction vessel. The reaction was stirred for 2 hours.

The obtained resin is washed with dimethylformamide, methylene chloride, methylene chloride containing 10% diisopropylethylamine, methylene chloride, and a mixture of methylene chloride and dimethylformamide, and Boc-Tyr (Cl ₂ -Bzl) -Pr
An o-resin was obtained. Successively, the same removal of Boc group and coupling of Boc and amino acid were repeated to obtain 20 ml of 10% resin.
Stir in hydrogen fluoride containing anisole at 0 ° C. for 1 hour,
The peptide was released from the resin. Hydrogen fluoride was distilled off under reduced pressure, the residue was extracted with 30% acetic acid, and lyophilized to obtain a crude peptide. This was purified by reverse phase chromatography using an ODS column (Cosmosil 5C ₁₈ ), and H-Asp-Tyr-Gl was purified.
y-Leu-Tyr-Pro-OH was synthesized.

 The physical properties of the peptide are as follows.

TLC [n-butanol: acetic acid: pyridine: water = 15: 3: 10: 1
2] (silica gel plates, ninhydrin coloring) Rf: 0.690 mp: 170 ℃ Elemental analysis _{C 35 H 46 N 6 O 11} · 0.8H 2 O as a C H N Calculated 56.72 6.47 11.34 measured value 56.64 6.41 11.39 Specific rotation ▲ [ α] ²⁵ _D ▼; (C = 0.5 water); −28.4 ゜ Example 1 (Measurement of angiotensin converting enzyme inhibitory activity) The measurement of angiotensin converting enzyme inhibitory activity was performed by Cheung
And Cushman's method (Biochemical Pharamacology 20, 1637)
(1971)] according to the following method.

Enzyme substrate: Bz (benzyl) -Gly-His-Leu (86 mg water
8 ml and a solution dissolved in 8 ml of phosphate buffer) Enzyme; rabbit lung acetone powder (manufactured by Sigma) (1 g is crushed in 10 ml of 50 mM phosphate buffer and centrifuged, and the supernatant is centrifuged) 100μ of the enzyme substrate, 12μ of the enzyme solution and the peptide of the present invention at a predetermined concentration were mixed, and the whole was mixed with water to 250μ.
After that, the reaction was carried out at 37 ° C. for 30 minutes.

The reaction was terminated using 250 μl of 1N HCl. 1.5 ml of ethyl acetate was added to the reaction-terminated liquid, followed by stirring with Vortex for 15 seconds, followed by centrifugation.

1.0 ml was taken out from the ethyl acetate layer, ethyl acetate was distilled off, 1 ml of distilled water was added to dissolve the residue, and the value of the ultraviolet absorption ₂₂₈ nm (OD ₂₂₈ ) of the extracted hippuric acid was measured.

Percent inhibition by the OD ₂₂₈ of when reacted without inhibitor as 100%, the concentration IC of the inhibitor when the OD ₂₂₈ of the inhibition rate of 50% determined as 0% when the reaction time of 0 minutes (the peptide of the present invention)
_The activity was indicated at ₅₀ (μM).

 The results are shown in Table 1.

In addition, as a reference example, an inhibitor other than the present invention was also measured, and is shown in Table 1.

[Effect] In the present invention, a novel peptide useful as an angiotensin converting enzyme inhibitor can be obtained.

──────────────────────────────────────────────────の Continuation of the front page (51) Int.Cl. ⁷ identification code FI C12N 9/99 A61K 37/64 // C07K 123: 00 (58) Field surveyed (Int.Cl. ⁷ , DB name) C07K 5 / 08-19/00 A61K 38/55 A61P 9/12 A61P 43/00 C12N 9/99 CA (STN) REGISTRY (STN) WPI (DIALOG) BIOSIS (DIALOG)

Claims (2)

(57) [Claims] 1. A novel peptide, Asp-Tyr-Gly-Leu-Tyr-Pro. 2. An angiotensin converting enzyme inhibitor comprising, as an active ingredient, a peptide called Asp-Tyr-Gly-Leu-Tyr-Pro.